Kaposi sarcoma pathogenesis: A triad of viral infection, oncogenesis and chronic inflammation

Translational Biomedicine

Volumn 1, Issue 2, 2010, Pages

  Douglas, Janet L ^a   Gustin, Jean K ^a   Moses, Ashlee V ^a   Dezube, Bruce J ^b   Pantanowitz, Liron ^c  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BEVACIZUMAB; BLEOMYCIN; CCL1 CHEMOKINE; CORTICOSTEROID; DAUNORUBICIN; DOXORUBICIN; ETOPOSIDE; FOSCARNET; G PROTEIN COUPLED RECEPTOR; GANCICLOVIR; HYDROXYDAUNORUBICIN; IMATINIB; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 6; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MITOGEN ACTIVATED PROTEIN KINASE 12; MONOCYTE CHEMOTACTIC PROTEIN 1; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PROTEINASE INHIBITOR; RAPAMYCIN; RITUXIMAB; THALIDOMIDE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VINBLASTINE; VINCRISTINE; VIRUS RNA;

ANGIOGENESIS; ARTICLE; CANCER CHEMOTHERAPY; CARCINOGENESIS; CELL DIFFERENTIATION; CHRONIC INFLAMMATION; DENDRITIC CELL; DISEASE COURSE; ERYTHROCYTE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN HERPESVIRUS 8; IMMUNE EVASION; IMMUNE RESPONSE; KAPOSI SARCOMA; MACROPHAGE; MICROBIOLOGY; MONOCYTE; ONCOGENE; OUTCOME ASSESSMENT; PATHOGENESIS; PROTEIN EXPRESSION; T LYMPHOCYTE; TUMOR CELL; VIRUS INFECTION;

EID: 84859642925     PISSN: None     EISSN: 21720479     Source Type: Journal    
DOI: 10.3823/409     Document Type: Article

References (165)

1. Martin, JN, Ganem, DE, Osmond, DH, Page-Shafer, KA, Macrae, D, et al. (1998) Sexual transmission and the natural history of human herpesvirus 8 infection. N Engl J Med. 338(14): p. 948-54.
2. Kestens, L, Melbye, M, Biggar, RJ, Stevens, WJ, Piot, P, et al. (1985) Endemic African Kaposi's sarcoma is not associated with immunodeficiency. Int J Cancer. 36(1): p. 49-54.
3. Rubin, AI and Stiller, MJ (2002) A listing of skin conditions exhibiting the koebner and pseudo-koebner phenomena with eliciting stimuli. J Cutan Med Surg. 6(1): p. 29-34.
4. Leidner, RS and Aboulafia, DM (2005) Recrudescent Kaposi's sarcoma after initiation of HAART: a manifestation of immune reconstitution syndrome. AIDS Patient Care STDS. 19(10): p. 635-44.
5. Ziegler, J and Dorfman, RF, Overview of kaposi's sarcoma: History, epidemiology, and biomedical features, in Kaposi's sarcoma: Pathophysiology and clinical management, J.L. Ziegler and R.F. Dorfman, Editors. 1988, Marcel Dekker, Inc.: New York. p. 1-22.
6. Hayward, GS (2003) Initiation of angiogenic Kaposi's sarcoma lesions. Cancer Cell. 3(1): p. 1-3.
7. Casper, C, Redman, M, Huang, ML, Pauk, J, Lampinen, TM, et al. (2004) HIV infection and human herpesvirus-8 oral shedding among men who have sex with men. J Acquir Immune Defic Syndr. 35(3): p. 233-8.
8. Chatlynne, LG and Ablashi, DV (1999) Seroepidemiology of Kaposi's sarcoma-associated herpesvirus (KSHV). Semin Cancer Biol. 9(3): p. 175-85.
9. Grayson, W and Pantanowitz, L (2008) Histological variants of cutaneous Kaposi sarcoma. Diagn Pathol. 3: p. 31.
10. O'Donnell, PJ, Pantanowitz, L, and Grayson, W (2010) Unique histologic variants of cutaneous Kaposi sarcoma. Am J Dermatopathol. 32(3): p. 244-50.
11. Konstantinopoulos, PA, Dezube, BJ, and Pantanowitz, L (2006) Morphologic and immunophenotypic evidence of in-situ Kaposi's sarcoma. BMC Clin Pathol. 6: p. 7.
12. Ruocco, V, Schwartz, RA, and Ruocco, E (2002) Lymphedema: an immunologically vulnerable site for development of neoplasms. J Am Acad Dermatol. 47(1): p. 124-7.
13. Pantanowitz, L, Fruh, K, Marconi, S, Moses, AV, and Dezube, BJ (2008) Pathology of rituximab-induced Kaposi sarcoma flare. BMC Clin Pathol. 8: p. 7.
14. Pantanowitz, L, Dezube, BJ, Pinkus, GS, and Tahan, SR (2004) Histological characterization of regression in acquired immunodeficiency syndrome-related Kaposi's sarcoma. J Cutan Pathol. 31(1): p. 26-34.
15. Gill, PS, Tsai, YC, Rao, AP, Spruck, CH, 3rd, Zheng, T, et al. (1998) Evidence for multiclonality in multicentric Kaposi's sarcoma. Proc Natl Acad Sci U S A. 95(14): p. 8257-61.
16. Duprez, R, Lacoste, V, Briere, J, Couppie, P, Frances, C, et al. (2007) Evidence for a multiclonal origin of multicentric advanced lesions of Kaposi sarcoma. J Natl Cancer Inst. 99(14): p. 1086-94.
17. Rabkin, CS, Janz, S, Lash, A, Coleman, AE, Musaba, E, et al. (1997) Monoclonal origin of multicentric Kaposi's sarcoma lesions. N Engl J Med. 336(14): p. 988-93.
18. Nickoloff, BJ (1993) PECAM-1 (CD31) is expressed on proliferating endothelial cells, stromal spindle-shaped cells, and dermal dendrocytes in Kaposi's sarcoma. Arch Dermatol. 129(2): p. 250-1.
19. Kaaya, EE, Parravicini, C, Ordonez, C, Gendelman, R, Berti, E, et al. (1995) Heterogeneity of spindle cells in Kaposi's sarcoma: comparison of cells in lesions and in culture. J Acquir Immune Defic Syndr Hum Retrovirol. 10(3): p. 295-305.
20. Regezi, JA, MacPhail, LA, Daniels, TE, DeSouza, YG, Greenspan, JS, et al. (1993) Human immunodeficiency virus-associated oral Kaposi's sarcoma. A heterogeneous cell population dominated by spindle-shaped endothelial cells. Am J Pathol. 143(1): p. 240-9.
21. Beckstead, JH, Wood, GS, and Fletcher, V (1985) Evidence for the origin of Kaposi's sarcoma from lymphatic endothelium. Am J Pathol. 119(2): p. 294-300.
22. Jussila, L, Valtola, R, Partanen, TA, Salven, P, Heikkila, P, et al. (1998) Lymphatic endothelium and Kaposi's sarcoma spindle cells detected by antibodies against the vascular endothelial growth factor receptor-3. Cancer Res. 58(8): p. 1599-604.
23. Kahn, HJ, Bailey, D, and Marks, A (2002) Monoclonal antibody D2-40, a new marker of lymphatic endothelium, reacts with Kaposi's sarcoma and a subset of angiosarcomas. Mod Pathol. 15(4): p. 434-40.
24. Nadimi, H, Saatee, S, Armin, A, and Toto, PD (1988) Expression of endothelial cell markers PAL-E and EN-4 and Ia-antigens in Kaposi's sarcoma. J Oral Pathol. 17(8): p. 416-20.
25. Xu, H, Edwards, JR, Espinosa, O, Banerji, S, Jackson, DG, et al. (2004) Expression of a lymphatic endothelial cell marker in benign and malignant vascular tumors. Hum Pathol. 35(7): p. 857-61.
26. Herndier, B and Ganem, D (2001) The biology of Kaposi's sarcoma. Cancer Treat Res. 104: p. 89-126.
27. Wang, HW, Trotter, MW, Lagos, D, Bourboulia, D, Henderson, S, et al. (2004) Kaposi sarcoma herpesvirus-induced cellular reprogramming contributes to the lymphatic endothelial gene expression in Kaposi sarcoma. Nat Genet. 36(7): p. 687-93.
28. Hong, YK, Foreman, K, Shin, JW, Hirakawa, S, Curry, CL, et al. (2004) Lymphatic reprogramming of blood vascular endothelium by Kaposi sarcoma-associated herpesvirus. Nat Genet. 36(7): p. 683-5.
29. Sivakumar, R, Sharma-Walia, N, Raghu, H, Veettil, MV, Sadagopan, S, et al. (2008) Kaposi's sarcoma-associated herpesvirus induces sustained levels of vascular endothelial growth factors A and C early during in vitro infection of human microvascular dermal endothelial cells: biological implications. J Virol. 82(4): p. 1759-76.
30. Hansen, A, Henderson, S, Lagos, D, Nikitenko, L, Coulter, E, et al. (2010) KSHV-encoded miRNAs target MAF to induce endothelial cell reprogramming. Genes Dev. 24(2): p. 195-205.
31. Pyakurel, P, Pak, F, Mwakigonja, AR, Kaaya, E, Heiden, T, et al. (2006) Lymphatic and vascular origin of Kaposi's sarcoma spindle cells during tumor development. Int J Cancer. 119(6): p. 1262-7.
32. Taddeo, A, Presicce, P, Brambilla, L, Bellinvia, M, Villa, ML, et al. (2008) Circulating Endothelial Progenitor Cells Are Increased in Patients with Classic Kaposi's Sarcoma. J Invest Dermatol.
33. Pellet, C, Kerob, D, Dupuy, A, Carmagnat, MV, Mourah, S, et al. (2006) Kaposi's sarcoma-associated herpesvirus viremia is associated with the progression of classic and endemic Kaposi's sarcoma. J Invest Dermatol. 126(3): p. 621-7.
34. Della Bella, S, Taddeo, A, Calabro, ML, Brambilla, L, Bellinvia, M, et al. (2008) Peripheral Blood Endothelial Progenitors as Potential Reservoirs of Kaposi's Sarcoma-Associated Herpesvirus. PLoS ONE. 3(1): p. e1520.
35. Henry, M, Uthman, A, Geusau, A, Rieger, A, Furci, L, et al. (1999) Infection of circulating CD34+ cells by HHV-8 in patients with Kaposi's sarcoma. J Invest Dermatol. 113(4): p. 613-6.
36. Miles, SA, Rezai, AR, Salazar-Gonzalez, JF, Vander Meyden, M, Stevens, RH, et al. (1990) AIDS Kaposi sarcoma-derived cells produce and respond to interleukin 6. Proc Natl Acad Sci U S A. 87(11): p. 4068-72.
37. Delli Bovi, P, Donti, E, Knowles, DM, 2nd, Friedman-Kien, A, Luciw, PA, et al. (1986) Presence of chromosomal abnormalities and lack of AIDS retrovirus DNA sequences in AIDS-associated Kaposi's sarcoma. Cancer Res. 46(12 Pt 1): p. 6333-8.
38. Flore, O, Rafii, S, Ely, S, O'Leary, JJ, Hyjek, EM, et al. (1998) Transformation of primary human endothelial cells by Kaposi's sarcoma-associated herpesvirus. Nature. 394(6693): p. 588-92.
39. Delgado, T, Carroll, PA, Punjabi, AS, Margineantu, D, Hockenbery, DM, et al. (2010) Induction of the Warburg effect by Kaposi's sarcoma herpesvirus is required for the maintenance of latently infected endothelial cells. Proc Natl Acad Sci U S A.
40. Mocroft, A, Youle, M, Gazzard, B, Morcinek, J, Halai, R, et al. (1996) Anti-herpesvirus treatment and risk of Kaposi's sarcoma in HIV infection. Royal Free/Chelsea and Westminster Hospitals Collaborative Group. Aids. 10(10): p. 1101-5.
41. Glesby, MJ, Hoover, DR, Weng, S, Graham, NM, Phair, JP, et al. (1996) Use of antiherpes drugs and the risk of Kaposi's sarcoma: data from the Multicenter AIDS Cohort Study. J Infect Dis. 173(6): p. 1477-80.
42. Martin, DF, Kuppermann, BD, Wolitz, RA, Palestine, AG, Li, H, et al. (1999) Oral ganciclovir for patients with cytomegalovirus retinitis treated with a ganciclovir implant. Roche Ganciclovir Study Group. N Engl J Med. 340(14): p. 1063-70.
43. Glaunsinger, B and Ganem, D (2004) Lytic KSHV infection inhibits host gene expression by accelerating global mRNA turnover. Mol Cell. 13(5): p. 713-23.
44. Moses, AV, Jarvis, MA, Raggo, C, Bell, YC, Ruhl, R, et al. (2002) Kaposi's sarcoma-associated herpesvirus-induced upregulation of the c-kit proto-oncogene, as identified by gene expression profiling, is essential for the transformation of endothelial cells. J Virol. 76(16): p. 8383-99.
45. Raggo, C, Ruhl, R, McAllister, S, Koon, H, Dezube, BJ, et al. (2005) Novel cellular genes essential for transformation of endothelial cells by Kaposi's sarcoma-associated herpesvirus. Cancer Res. 65(12): p. 5084-95.
46. Poole, LJ, Yu, Y, Kim, PS, Zheng, QZ, Pevsner, J, et al. (2002) Altered patterns of cellular gene expression in dermal microvascular endothelial cells infected with Kaposi's sarcoma-associated herpesvirus. J Virol. 76(7): p. 3395-420.
47. Cornelissen, M, van der Kuyl, AC, van den Burg, R, Zorgdrager, F, van Noesel, CJ, et al. (2003) Gene expression profile of AIDS-related Kaposi's sarcoma. BMC Cancer. 3: p. 7.
48. McAllister, SC, Hansen, SG, Ruhl, RA, Raggo, CM, DeFilippis, VR, et al. (2004) Kaposi sarcoma-associated herpesvirus (KSHV) induces heme oxygenase-1 expression and activity in KSHV-infected endothelial cells. Blood. 103(9): p. 3465-73.
49. Rossi, G, Sartori, G, Rusev, BC, and Sgambato, A (2009) Expression and molecular analysis of c-kit and PDGFRs in Kaposi's sarcoma of different stages and epidemiological settings. Histopathology. 54(5): p. 619-22.
50. Ramirez-Amador, V, Martinez-Mata, G, Gonzalez-Ramirez, I, Anaya-Saavedra, G, and de Almeida, OP (2009) Clinical, histological and immunohistochemical findings in oral Kaposi's sarcoma in a series of Mexican AIDS patients. Comparative study. J Oral Pathol Med. 38(4): p. 328-33.
51. Douglas, JL, Whitford, JG, and Moses, AV (2009) Characterization of c-Kit expression and activation in KSHV-infected endothelial cells. Virology. 390(2): p. 174-85.
52. Lennartsson, J and Ronnstrand, L (2006) The stem cell factor receptor/c-Kit as a drug target in cancer. Curr Cancer Drug Targets. 6(1): p. 65-75.
53. Burns, JM, Summers, BC, Wang, Y, Melikian, A, Berahovich, R, et al. (2006) A novel chemokine receptor for SDF-1 and I-TAC involved in cell survival, cell adhesion, and tumor development. J Exp Med. 203(9): p. 2201-13.
54. Fonsato, V, Buttiglieri, S, Deregibus, MC, Bussolati, B, Caselli, E, et al. (2007) PAX2 expression by HHV-8-infected endothelial cells induced a pro-angiogenic and pro-invasive phenotype. Blood.
55. Djerbi, M, Screpanti, V, Catrina, AI, Bogen, B, Biberfeld, P, et al. (1999) The inhibitor of death receptor signaling, FLICE-inhibitory protein defines a new class of tumor progression factors. J Exp Med. 190(7): p. 1025-32.
56. Wang, S, Wang, S, Maeng, H, Young, DP, Prakash, O, et al. (2007) K1 protein of human herpesvirus 8 suppresses lymphoma cell Fas-mediated apoptosis. Blood. 109(5): p. 2174-82.
57. Gwack, Y, Hwang, S, Byun, H, Lim, C, Kim, JW, et al. (2001) Kaposi's sarcoma-associated herpesvirus open reading frame 50 represses p53-induced transcriptional activity and apoptosis. J Virol. 75(13): p. 6245-8.
58. Park, J, Seo, T, Hwang, S, Lee, D, Gwack, Y, et al. (2000) The K-bZIP protein from Kaposi's sarcoma-associated herpesvirus interacts with p53 and represses its transcriptional activity. J Virol. 74(24): p. 11977-82.
59. Wang, HW, Sharp, TV, Koumi, A, Koentges, G, and Boshoff, C (2002) Characterization of an anti-apoptotic glycoprotein encoded by Kaposi's sarcoma-associated herpesvirus which resembles a spliced variant of human survivin. Embo J. 21(11): p. 2602-15.
60. Feng, P, Scott, CW, Cho, NH, Nakamura, H, Chung, YH, et al. (2004) Kaposi's sarcoma-associated herpesvirus K7 protein targets a ubiquitin-like/ubiquitin-associated domain-containing protein to promote protein degradation. Mol Cell Biol. 24(9): p. 3938-48.
61. Lee, HR, Toth, Z, Shin, YC, Lee, JS, Chang, H, et al. (2009) Kaposi's sarcoma-associated herpesvirus viral interferon regulatory factor 4 targets MDM2 to deregulate the p53 tumor suppressor pathway. J Virol. 83(13): p. 6739-47.
62. Sarid, R, Sato, T, Bohenzky, RA, Russo, JJ, and Chang, Y (1997) Kaposi's sarcoma-associated herpesvirus encodes a functional bcl-2 homologue. Nat Med. 3(3): p. 293-8.
63. Krishnan, HH, Naranatt, PP, Smith, MS, Zeng, L, Bloomer, C, et al. (2004) Concurrent expression of latent and a limited number of lytic genes with immune modulation and antiapoptotic function by Kaposi's sarcoma-associated herpesvirus early during infection of primary endothelial and fibroblast cells and subsequent decline of lytic gene expression. J Virol. 78(7): p. 3601-20.
64. Weiss, G, Shemer, A, and Trau, H (2002) The Koebner phenomenon: review of the literature. J Eur Acad Dermatol Venereol. 16(3): p. 241-8.
65. Nicholas, J (2005) Human gammaherpesvirus cytokines and chemokine receptors. J Interferon Cytokine Res. 25(7): p. 373-83.
66. Kledal, TN, Rosenkilde, MM, Coulin, F, Simmons, G, Johnsen, AH, et al. (1997) A broad-spectrum chemokine antagonist encoded by Kaposi's sarcoma-associated herpesvirus. Science. 277(5332): p. 1656-9.
67. Weber, KS, Grone, HJ, Rocken, M, Klier, C, Gu, S, et al. (2001) Selective recruitment of Th2-type cells and evasion from a cytotoxic immune response mediated by viral macrophage inhibitory protein-II. Eur J Immunol. 31(8): p. 2458-66.
68. Cannon, M (2007) The KSHV and other human herpesviral G proteincoupled receptors. Curr Top Microbiol Immunol. 312: p. 137-56.
69. Karin, M and Greten, FR (2005) NF-kappaB: linking inflammation and immunity to cancer development and progression. Nat Rev Immunol. 5(10): p. 749-59.
70. Ono, M (2008) Molecular links between tumor angiogenesis and inflammation: inflammatory stimuli of macrophages and cancer cells as targets for therapeutic strategy. Cancer Sci. 99(8): p. 1501-6.
71. Schwarz, M and Murphy, PM (2001) Kaposi's sarcoma-associated herpesvirus G protein-coupled receptor constitutively activates NFkappa B and induces proinflammatory cytokine and chemokine production via a C-terminal signaling determinant. J Immunol. 167(1): p. 505-13.
72. Pati, S, Cavrois, M, Guo, HG, Foulke, JS, Jr., Kim, J, et al. (2001) Activation of NF-kappaB by the human herpesvirus 8 chemokine receptor ORF74: evidence for a paracrine model of Kaposi's sarcoma pathogenesis. J Virol. 75(18): p. 8660-73.
73. Sadler, R, Wu, L, Forghani, B, Renne, R, Zhong, W, et al. (1999) A complex translational program generates multiple novel proteins from the latently expressed kaposin (K12) locus of Kaposi's sarcoma-associated herpesvirus. J Virol. 73(7): p. 5722-30.
74. McCormick, C and Ganem, D (2005) The kaposin B protein of KSHV activates the p38/MK2 pathway and stabilizes cytokine mRNAs. Science. 307(5710): p. 739-41.
75. Yoshizaki, K, Matsuda, T, Nishimoto, N, Kuritani, T, Taeho, L, et al. (1989) Pathogenic significance of interleukin-6 (IL-6/BSF-2) in Castleman's disease. Blood. 74(4): p. 1360-7.
76. Stahl, N, Boulton, TG, Farruggella, T, Ip, NY, Davis, S, et al. (1994) Association and activation of Jak-Tyk kinases by CNTF-LIF-OSM-IL-6 beta receptor components. Science. 263(5143): p. 92-5.
77. Lutticken, C, Wegenka, UM, Yuan, J, Buschmann, J, Schindler, C, et al. (1994) Association of transcription factor APRF and protein kinase Jak1 with the interleukin-6 signal transducer gp130. Science. 263(5143): p. 89-92.
78. Fukada, T, Hibi, M, Yamanaka, Y, Takahashi-Tezuka, M, Fujitani, Y, et al. (1996) Two signals are necessary for cell proliferation induced by a cytokine receptor gp130: involvement of STAT3 in anti-apoptosis. Immunity. 5(5): p. 449-60.
79. Oh, H, Fujio, Y, Kunisada, K, Hirota, H, Matsui, H, et al. (1998) Activation of phosphatidylinositol 3-kinase through glycoprotein 130 induces protein kinase B and p70 S6 kinase phosphorylation in cardiac myocytes. J Biol Chem. 273(16): p. 9703-10.
80. Sharma-Walia, N, Paul, AG, Bottero, V, Sadagopan, S, Veettil, MV, et al. (2010) Kaposi's sarcoma associated herpes virus (KSHV) induced COX-2: a key factor in latency, inflammation, angiogenesis, cell survival and invasion. PLoS Pathog. 6(2): p. e1000777.
81. Stallone, G, Schena, A, Infante, B, Di Paolo, S, Loverre, A, et al. (2005) Sirolimus for Kaposi's sarcoma in renal-transplant recipients. N Engl J Med. 352(13): p. 1317-23.
82. Gutierrez-Dalmau, A, Sanchez-Fructuoso, A, Sanz-Guajardo, A, Mazuecos, A, Franco, A, et al. (2005) Efficacy of conversion to sirolimus in posttransplantation Kaposi's sarcoma. Transplant Proc. 37(9): p. 3836-8.
83. Lebbe, C, Euvrard, S, Barrou, B, Pouteil-Noble, C, Garnier, JL, et al. (2006) Sirolimus conversion for patients with posttransplant Kaposi's sarcoma. Am J Transplant. 6(9): p. 2164-8.
84. O'Byrne, KJ, Dalgleish, AG, Browning, MJ, Steward, WP, and Harris, AL (2000) The relationship between angiogenesis and the immune response in carcinogenesis and the progression of malignant disease. Eur J Cancer. 36(2): p. 151-69.
85. Cohen, T, Nahari, D, Cerem, LW, Neufeld, G, and Levi, BZ (1996) Interleukin 6 induces the expression of vascular endothelial growth factor. J Biol Chem. 271(2): p. 736-41.
86. Aoki, Y, Jaffe, ES, Chang, Y, Jones, K, Teruya-Feldstein, J, et al. (1999) Angiogenesis and hematopoiesis induced by Kaposi's sarcoma-associated herpesvirus-encoded interleukin-6. Blood. 93(12): p. 4034-43.
87. Boshoff, C, Endo, Y, Collins, PD, Takeuchi, Y, Reeves, JD, et al. (1997) Angiogenic and HIV-inhibitory functions of KSHV-encoded chemokines. Science. 278(5336): p. 290-4.
88. Stine, JT, Wood, C, Hill, M, Epp, A, Raport, CJ, et al. (2000) KSHV-encoded CC chemokine vMIP-III is a CCR4 agonist, stimulates angiogenesis, and selectively chemoattracts TH2 cells. Blood. 95(4): p. 1151-7.
89. Liu, C, Okruzhnov, Y, Li, H, and Nicholas, J (2001) Human herpesvirus 8 (HHV-8)-encoded cytokines induce expression of and autocrine signaling by vascular endothelial growth factor (VEGF) in HHV-8-infected primary-effusion lymphoma cell lines and mediate VEGF-independent antiapoptotic effects. J Virol. 75(22): p. 10933-40.
90. Bais, C, Santomasso, B, Coso, O, Arvanitakis, L, Raaka, EG, et al. (1998) G-protein-coupled receptor of Kaposi's sarcoma-associated herpesvirus is a viral oncogene and angiogenesis activator. Nature. 391(6662): p. 86-9.
91. Bais, C, Van Geelen, A, Eroles, P, Mutlu, A, Chiozzini, C, et al. (2003) Kaposi's sarcoma associated herpesvirus G protein-coupled receptor immortalizes human endothelial cells by activation of the VEGF receptor-2/ KDR. Cancer Cell. 3(2): p. 131-43.
92. Wang, L, Wakisaka, N, Tomlinson, CC, DeWire, SM, Krall, S, et al. (2004) The Kaposi's sarcoma-associated herpesvirus (KSHV/HHV-8) K1 protein induces expression of angiogenic and invasion factors. Cancer Res. 64(8): p. 2774-81.
93. Deryugina, EI and Quigley, JP (2006) Matrix metalloproteinases and tumor metastasis. Cancer Metastasis Rev. 25(1): p. 9-34.
94. Impola, U, Cuccuru, MA, Masala, MV, Jeskanen, L, Cottoni, F, et al. (2003) Preliminary communication: matrix metalloproteinases in Kaposi's sarcoma. Br J Dermatol. 149(4): p. 905-7.
95. Meade-Tollin, LC, Way, D, and Witte, MH (1999) Expression of multiple matrix metalloproteinases and urokinase type plasminogen activator in cultured Kaposi sarcoma cells. Acta Histochem. 101(3): p. 305-16.
96. Cianfrocca, M, Cooley, TP, Lee, JY, Rudek, MA, Scadden, DT, et al. (2002) Matrix metalloproteinase inhibitor COL-3 in the treatment of AIDS-related Kaposi's sarcoma: a phase I AIDS malignancy consortium study. J Clin Oncol. 20(1): p. 153-9.
97. Bergers, G, Brekken, R, McMahon, G, Vu, TH, Itoh, T, et al. (2000) Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis. Nat Cell Biol. 2(10): p. 737-44.
98. Qian, LW, Xie, J, Ye, F, and Gao, SJ (2007) Kaposi's Sarcoma-Associated Herpesvirus Infection Promotes Invasion of Primary Human Umbilical Vein Endothelial Cells by Inducing Matrix Metalloproteinases. J Virol.
99. Qin, Z, Dai, L, Slomiany, MG, Toole, BP, and Parsons, C (2010) Direct activation of emmprin and associated pathogenesis by an oncogenic herpesvirus. Cancer Res. 70(10): p. 3884-9.
100. Brown, LF, Dezube, BJ, Tognazzi, K, Dvorak, HF, and Yancopoulos, GD (2000) Expression of Tie1, Tie2, and angiopoietins 1, 2, and 4 in Kaposi's sarcoma and cutaneous angiosarcoma. Am J Pathol. 156(6): p. 2179-83.
101. Ye, FC, Blackbourn, DJ, Mengel, M, Xie, JP, Qian, LW, et al. (2007) Kaposi's sarcoma-associated herpesvirus promotes angiogenesis by inducing angiopoietin-2 expression via AP-1 and Ets1. J Virol. 81(8): p. 3980-91.
102. Takeda, N, Maemura, K, Imai, Y, Harada, T, Kawanami, D, et al. (2004) Endothelial PAS domain protein 1 gene promotes angiogenesis through the transactivation of both vascular endothelial growth factor and its receptor, Flt-1. Circ Res. 95(2): p. 146-53.
103. Sodhi, A, Montaner, S, Patel, V, Zohar, M, Bais, C, et al. (2000) The Kaposi's sarcoma-associated herpes virus G protein-coupled receptor up-regulates vascular endothelial growth factor expression and secretion through mitogen-activated protein kinase and p38 pathways acting on hypoxia-inducible factor 1alpha. Cancer Res. 60(17): p. 4873-80.
104. Carroll, PA, Kenerson, HL, Yeung, RS, and Lagunoff, M (2006) Latent Kaposi's sarcoma-associated herpesvirus infection of endothelial cells activates hypoxia-induced factors. J Virol. 80(21): p. 10802-12.
105. Koon, HB, Pantanowitz, L, and Dezube, BJ, Antiangiogenic Therapy for Kaposi's sarcoma, in Anti-angiogenic cancer therapy, D. Davis, R.S. Herbst, and J.L. Abbruzzese, Editors. 2007, CRC. p. 753-781.
106. Dezube, BJ, Pantanowitz, L, and Aboulafia, DM (2004) Management of AIDS-related Kaposi sarcoma: advances in target discovery and treatment. AIDS Read. 14(5): p. 236-8, 243-4, 251-3.
107. Di Lorenzo, G, Konstantinopoulos, PA, Pantanowitz, L, Di Trolio, R, De Placido, S, et al. (2007) Management of AIDS-related Kaposi's sarcoma. Lancet Oncol. 8(2): p. 167-76.
108. Sullivan, RJ, Pantanowitz, L, and Dezube, BJ (2009) Targeted therapy for Kaposi sarcoma. BioDrugs. 23(2): p. 69-75.
109. Arav-Boger, R (2009) Treatment for Kaposi sarcoma herpesvirus: great challenges with promising accomplishments. Virus Genes. 38(2): p. 195-203.
110. Ledergerber, B, Telenti, A, and Egger, M (1999) Risk of HIV related Kaposi's sarcoma and non-Hodgkin's lymphoma with potent antiretroviral therapy: prospective cohort study. Swiss HIV Cohort Study. Bmj. 319(7201): p. 23-4.
111. Little, RF, Wyvill, KM, Pluda, JM, Welles, L, Marshall, V, et al. (2000) Activity of thalidomide in AIDS-related Kaposi's sarcoma. J Clin Oncol. 18(13): p. 2593-602.
112. Koon, HB, Bubley, GJ, Pantanowitz, L, Masiello, D, Smith, B, et al. (2005) Imatinib-induced regression of AIDS-related Kaposi's sarcoma. J Clin Oncol. 23(5): p. 982-9.
113. Dezube, BJ, Krown, SE, Lee, JY, Bauer, KS, and Aboulafia, DM (2006) Randomized phase II trial of matrix metalloproteinase inhibitor COL-3 in AIDS-related Kaposi's sarcoma: an AIDS Malignancy Consortium Study. J Clin Oncol. 24(9): p. 1389-94.
114. Merimsky, O, Jiveliouk, I, and Sagi-Eisenberg, R (2008) Targeting mTOR in HIV-Negative Classic Kaposi's Sarcoma. Sarcoma. 2008: p. 825093.
115. Guenova, E, Metzler, G, Hoetzenecker, W, Berneburg, M, and Rocken, M (2008) Classic Mediterranean Kaposi's sarcoma regression with sirolimus treatment. Arch Dermatol. 144(5): p. 692-3.
116. Chang, H, Wachtman, LM, Pearson, CB, Lee, JS, Lee, HR, et al. (2009) Non-human primate model of Kaposi's sarcoma-associated herpesvirus infection. PLoS Pathog. 5(10): p. e1000606.
117. Jia, Q, Freeman, ML, Yager, EJ, McHardy, I, Tong, L, et al. (2010) Induction of protective immunity against murine gammaherpesvirus 68 infection in the absence of viral latency. J Virol. 84(5): p. 2453-65.
118. Pantanowitz, L and Dezube, BJ (2004) Advances in the pathobiology and treatment of Kaposi sarcoma. Curr Opin Oncol. 16(5): p. 443-9.
119. Dourmishev, LA, Dourmishev, AL, Palmeri, D, Schwartz, RA, and Lukac, DM (2003) Molecular genetics of Kaposi's sarcoma-associated herpesvirus (human herpesvirus-8) epidemiology and pathogenesis. Microbiol Mol Biol Rev. 67(2): p. 175-212, table of contents.
120. Chandriani, S and Ganem, D (2010) Array-based transcript profiling and limiting-dilution reverse transcription-PCR analysis identify additional latent genes in Kaposi's sarcoma-associated herpesvirus. J Virol. 84(11): p. 5565-73.
121. Ganem, D (2006) KSHV infection and the pathogenesis of Kaposi's sarcoma. Annu Rev Pathol. 1: p. 273-96.
122. Di Bartolo, DL, Cannon, M, Liu, YF, Renne, R, Chadburn, A, et al. (2008) KSHV LANA inhibits TGF-{beta} signaling through epigenetic silencing of the TGF-{beta} type II receptor. Blood.
123. Laman, H, Coverley, D, Krude, T, Laskey, R, and Jones, N (2001) Viral cyclin-cyclin-dependent kinase 6 complexes initiate nuclear DNA replication. Mol Cell Biol. 21(2): p. 624-35.
124. Verschuren, EW, Hodgson, JG, Gray, JW, Kogan, S, Jones, N, et al. (2004) The role of p53 in suppression of KSHV cyclin-induced lymphomagenesis. Cancer Res. 64(2): p. 581-9.
125. Sun, Q, Zachariah, S, and Chaudhary, PM (2003) The human herpes virus 8-encoded viral FLICE-inhibitory protein induces cellular transformation via NF-kappaB activation. J Biol Chem. 278(52): p. 52437-45.
126. Chugh, P, Matta, H, Schamus, S, Zachariah, S, Kumar, A, et al. (2005) Constitutive NF-kappaB activation, normal Fas-induced apoptosis, and increased incidence of lymphoma in human herpes virus 8 K13 transgenic mice. Proc Natl Acad Sci U S A. 102(36): p. 12885-90.
127. Guasparri, I, Keller, SA, and Cesarman, E (2004) KSHV vFLIP is essential for the survival of infected lymphoma cells. J Exp Med. 199(7): p. 993-1003.
128. Efklidou, S, Bailey, R, Field, N, Noursadeghi, M, and Collins, MK (2008) vFLIP from KSHV inhibits anoikis of primary endothelial cells. J Cell Sci.
129. Guasparri, I, Wu, H, and Cesarman, E (2006) The KSHV oncoprotein vFLIP contains a TRAF-interacting motif and requires TRAF2 and TRAF3 for signalling. EMBO Rep. 7(1): p. 114-9.
130. Samols, MA, Hu, J, Skalsky, RL, and Renne, R (2005) Cloning and identification of a microRNA cluster within the latency-associated region of Kaposi's sarcoma-associated herpesvirus. J Virol. 79(14): p. 9301-5.
131. Cai, X and Cullen, BR (2006) Transcriptional origin of Kaposi's sarcoma-associated herpesvirus microRNAs. J Virol. 80(5): p. 2234-42.
132. Pfeffer, S, Sewer, A, Lagos-Quintana, M, Sheridan, R, Sander, C, et al. (2005) Identification of microRNAs of the herpesvirus family. Nat Methods. 2(4): p. 269-76.
133. Grundhoff, A, Sullivan, CS, and Ganem, D (2006) A combined computational and microarray-based approach identifies novel microRNAs encoded by human gamma-herpesviruses. Rna. 12(5): p. 733-50.
134. Gottwein, E, Mukherjee, N, Sachse, C, Frenzel, C, Majoros, WH, et al. (2007) A viral microRNA functions as an orthologue of cellular miR-155. Nature. 450(7172): p. 1096-9.
135. Skalsky, RL, Samols, MA, Plaisance, KB, Boss, IW, Riva, A, et al. (2007) Kaposi's sarcoma-associated herpesvirus encodes an ortholog of miR-155. J Virol. 81(23): p. 12836-45.
136. Calame, K (2007) MicroRNA-155 function in B Cells. Immunity. 27(6): p. 825-7.
137. Ziegelbauer, JM, Sullivan, CS, and Ganem, D (2009) Tandem arraybased expression screens identify host mRNA targets of virus-encoded microRNAs. Nat Genet. 41(1): p. 130-4.
138. Nachmani, D, Stern-Ginossar, N, Sarid, R, and Mandelboim, O (2009) Diverse herpesvirus microRNAs target the stress-induced immune ligand MICB to escape recognition by natural killer cells. Cell Host Microbe. 5(4): p. 376-85.
139. Samols, MA, Skalsky, RL, Maldonado, AM, Riva, A, Lopez, MC, et al. (2007) Identification of cellular genes targeted by KSHV-encoded microRNAs. PLoS Pathog. 3(5): p. e65.
140. Bellare, P and Ganem, D (2009) Regulation of KSHV lytic switch protein expression by a virus-encoded microRNA: an evolutionary adaptation that fine-tunes lytic reactivation. Cell Host Microbe. 6(6): p. 570-5.
141. Lu, F, Stedman, W, Yousef, M, Renne, R, and Lieberman, PM (2010) Epigenetic regulation of Kaposi's sarcoma-associated herpesvirus latency by virus-encoded microRNAs that target Rta and the cellular Rbl2-DNMT pathway. J Virol. 84(6): p. 2697-706.
142. Lei, X, Bai, Z, Ye, F, Xie, J, Kim, CG, et al. (2010) Regulation of NF-kappaB inhibitor IkappaBalpha and viral replication by a KSHV microRNA. Nat Cell Biol. 12(2): p. 193-9.
143. Gottwein, E and Cullen, BR (2010) A human herpesvirus microRNA inhibits p21 expression and attenuates p21-mediated cell cycle arrest. J Virol. 84(10): p. 5229-37.
144. Lagunoff, M, Majeti, R, Weiss, A, and Ganem, D (1999) Deregulated signal transduction by the K1 gene product of Kaposi's sarcoma-associated herpesvirus. Proc Natl Acad Sci U S A. 96(10): p. 5704-9.
145. Lee, H, Guo, J, Li, M, Choi, JK, DeMaria, M, et al. (1998) Identification of an immunoreceptor tyrosine-based activation motif of K1 transforming protein of Kaposi's sarcoma-associated herpesvirus. Mol Cell Biol. 18(9): p. 5219-28.
146. Lee, H, Veazey, R, Williams, K, Li, M, Guo, J, et al. (1998) Deregulation of cell growth by the K1 gene of Kaposi's sarcoma-associated herpesvirus. Nat Med. 4(4): p. 435-40.
147. Prakash, O, Tang, ZY, Peng, X, Coleman, R, Gill, J, et al. (2002) Tumorigenesis and aberrant signaling in transgenic mice expressing the human herpesvirus-8 K1 gene. J Natl Cancer Inst. 94(12): p. 926-35.
148. Prakash, O, Swamy, OR, Peng, X, Tang, ZY, Li, L, et al. (2005) Activation of Src kinase Lyn by the Kaposi sarcoma-associated herpesvirus K1 protein: implications for lymphomagenesis. Blood. 105(10): p. 3987-94.
149. Wang, L, Dittmer, DP, Tomlinson, CC, Fakhari, FD, and Damania, B (2006) Immortalization of primary endothelial cells by the K1 protein of Kaposi's sarcoma-associated herpesvirus. Cancer Res. 66(7): p. 3658-66.
150. Offermann, MK (2007) Kaposi sarcoma herpesvirus-encoded interferon regulator factors. Curr Top Microbiol Immunol. 312: p. 185-209.
151. Jayachandra, S, Low, KG, Thlick, AE, Yu, J, Ling, PD, et al. (1999) Three unrelated viral transforming proteins (vIRF, EBNA2, and E1A) induce the MYC oncogene through the interferon-responsive PRF element by using different transcription coadaptors. Proc Natl Acad Sci U S A. 96(20): p. 11566-71.
152. Areste, C and Blackbourn, DJ (2009) Modulation of the immune system by Kaposi's sarcoma-associated herpesvirus. Trends Microbiol. 17(3): p. 119-29.
153. Kanno, T, Sato, Y, Sata, T, and Katano, H (2006) Expression of Kaposi's sarcoma-associated herpesvirus-encoded K10/10.1 protein in tissues and its interaction with poly(A)-binding protein. Virology. 352(1): p. 100-9.
154. Yu, Y, Wang, SE, and Hayward, GS (2005) The KSHV immediate-early transcription factor RTA encodes ubiquitin E3 ligase activity that targets IRF7 for proteosome-mediated degradation. Immunity. 22(1): p. 59-70.
155. Chatterjee, M, Osborne, J, Bestetti, G, Chang, Y, and Moore, PS (2002) Viral IL-6-induced cell proliferation and immune evasion of interferon activity. Science. 298(5597): p. 1432-5.
156. Cloutier, N and Flamand, L (2010) Kaposi sarcoma-associated herpesvirus latency-associated nuclear antigen inhibits interferon (IFN) beta expression by competing with IFN regulatory factor-3 for binding to IFNB promoter. J Biol Chem. 285(10): p. 7208-21.
157. Lagos, D, Pollara, G, Henderson, S, Gratrix, F, Fabani, M, et al. (2010) miR-132 regulates antiviral innate immunity through suppression of the p300 transcriptional co-activator. Nat Cell Biol. 12(5): p. 513-9.
158. Mullick, J, Bernet, J, Singh, AK, Lambris, JD, and Sahu, A (2003) Kaposi's sarcoma-associated herpesvirus (human herpesvirus 8) open reading frame 4 protein (kaposica) is a functional homolog of complement control proteins. J Virol. 77(6): p. 3878-81.
159. Spiller, OB, Robinson, M, O'Donnell, E, Milligan, S, Morgan, BP, et al. (2003) Complement regulation by Kaposi's sarcoma-associated herpesvirus ORF4 protein. J Virol. 77(1): p. 592-9.
160. Coscoy, L and Ganem, D (2001) A viral protein that selectively downregulates ICAM-1 and B7-2 and modulates T cell costimulation. J Clin Invest. 107(12): p. 1599-606.
161. Sanchez, DJ, Gumperz, JE, and Ganem, D (2005) Regulation of CD1d expression and function by a herpesvirus infection. J Clin Invest. 115(5): p. 1369-78.
162. Mansouri, M, Douglas, J, Rose, PP, Gouveia, K, Thomas, G, et al. (2006) Kaposi sarcoma herpesvirus K5 removes CD31/PECAM from endothelial cells. Blood. 108(6): p. 1932-40.
163. Bartee, E, McCormack, A, and Fruh, K (2006) Quantitative membrane proteomics reveals new cellular targets of viral immune modulators. PLoS Pathog. 2(10): p. e107.
164. Mansouri, M, Viswanathan, K, Douglas, JL, Hines, J, Gustin, J, et al. (2009) Molecular mechanism of BST2/tetherin downregulation by K5/MIR2 of Kaposi's sarcoma-associated herpesvirus. J Virol. 83(19): p. 9672-81.
165. Lagos, D, Trotter, MW, Vart, RJ, Wang, HW, Matthews, NC, et al. (2007) Kaposi sarcoma herpesvirus-encoded vFLIP and vIRF1 regulate antigen presentation in lymphatic endothelial cells. Blood. 109(4): p. 1550-8.